Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

(2019) William D Tap et al.   LANCET

Burden of Illness Associated with Tenosynovial Giant Cell Tumors

(2018) Tanya M. Burton et al.   CLINICAL THERAPEUTICS

Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial

(2018) Hans Gelderblom et al.   LANCET ONCOLOGY

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

(2016) Heather L. Gelhorn et al.   CLINICAL THERAPEUTICS

Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors

(2015) Emanuela Palmerini et al.   EUROPEAN JOURNAL OF CANCER

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

(2015) Philippe A Cassier et al.   LANCET ONCOLOGY

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

(2015) William D. Tap et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

(2014) Carola H. Ries et al.   CANCER CELL

Long-term follow-up results of primary and recurrent pigmented villonodular synovitis

(2014) Floortje G. M. Verspoor et al.   RHEUMATOLOGY

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis

(2011) Philippe A. Cassier et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER